Inside the KLOW Stack: KLOW Peptide as Four Named Processes

TL;DR — the four processes

KLOW peptide is four separate peptides in one vial. Each has its own research history, its own molecular weight, its own mechanism, and its own regulatory status. None of the four is FDA-approved. The combination of all four has never been studied. Reading the klow stack means reading four separate literatures — which is what this page does.

Process 1: KPV — the anti-inflammatory arm

KPV (Lysine-Proline-Valine, CAS 67727-97-3, MW 342.44 Da). The C-terminal residues 11-13 of the 13-amino-acid alpha-MSH (alpha-melanocyte-stimulating hormone). A linear tripeptide: L-Lys-L-Pro-L-Val.

Role in the blend: 10 mg of the 80 mg total vial (~12.5% by mass). KPV is the anti-inflammatory arm. Its primary mechanism is inhibition of NF-κB p65 nuclear import in epithelial and immune cells — blocking the transcription factor (a protein that switches genes on) that drives production of pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β. It also suppresses MAPK (mitogen-activated protein kinase) ERK and p38 inflammatory signaling.

KPV is a substrate of PepT1 (SLC15A1), the di/tripeptide transporter upregulated in inflamed intestinal cells, with a Km of approximately 160 μM — meaning it is actively taken up into inflamed gut epithelium and macrophages at physiologically relevant concentrations ^[6].

In published rodent studies, oral KPV reduced the severity of DSS-induced and TNBS-induced colitis in C57BL/6 mice ^[6]. No controlled KPV monotherapy trial has reached regulatory approval. Human data are limited to delivery mechanism studies.

Process 2: GHK-Cu — the matrix and copper arm

GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper(II), Copper Tripeptide-1, CAS 89030-95-5, MW 402.92 Da). A naturally occurring tripeptide Gly-His-Lys chelated 1:1 to a Cu(II) ion. First isolated from human plasma by Loren Pickart in 1973. Plasma GHK declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60 ^[5].

Role in the blend: 50 mg of the 80 mg total vial (~62.5% by mass). GHK-Cu is the mass-dominant component — more than half the vial by weight. It is a broad transcriptomic modulator: GHK altered expression of approximately 31.2% of human genes at a 50%-or-greater change threshold, with strongest signals on extracellular-matrix remodeling, antioxidant defense, DNA repair, and anti-inflammatory pathways ^[7]. GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate, and decorin, and supplies copper for lysyl oxidase — the copper-dependent enzyme that crosslinks collagen and elastin ^[5].

GHK-Cu has decades of topical cosmetic and wound-healing human data in cosmetic formulations. It has no approved systemic indication. The copper in each molecule is chelated copper(II); for individuals with copper-handling disorders such as Wilson's disease, the copper load is a theoretical caution.

Process 3: BPC-157 — the angiogenic arm

BPC-157 (Body Protection Compound 157, PL 14736, CAS 137525-51-0, MW 1419.53 Da). Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. A synthetic 15-amino-acid peptide derived from a partial sequence of a protein identified in human gastric juice. Originally developed as PL 14736 for inflammatory bowel disease.

Role in the blend: 10 mg of the 80 mg vial (~12.5% by mass). BPC-157 is the primary angiogenic arm. Its lead mechanism is activation of the VEGFR2/PI3K/Akt/eNOS angiogenic cascade — a signaling chain that promotes new blood-vessel formation and endothelial function ^[1]. It also modulates vasomotor tone via Src-Caveolin-1-eNOS ^[2] and upregulates the growth-hormone receptor in tendon fibroblasts (cells that produce tendon connective tissue). BPC-157 accelerated healing of a fully transected rat Achilles tendon at doses of 10 μg, 10 ng, and 10 pg per rat ^[9].

Human data: one 2025 IV safety pilot in two healthy adults (10 mg day 1, 20 mg day 2) showed no adverse events and no changes in safety biomarkers ^[17]. This is a safety observation in two people, not an efficacy trial. BPC-157 is not FDA-approved and is under 503A bulk-substance review as a Category 2 compound.

BPC-157 has a very short elimination half-life in rodent pharmacokinetic observations — under approximately 30 minutes — which creates a pharmacokinetic mismatch with the other three components when all are co-dissolved in one vial.

Process 4: TB-500 — the cytoskeletal arm

TB-500 (Ac-LKKTETQ, MW 889.02 Da). A synthetic N-acetylated heptapeptide: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln. This is the LKKTET actin-binding motif of the 43-amino-acid native protein thymosin beta-4 (Tβ4). Important distinction: TB-500 is a fragment; most foundational efficacy data are for the full-length native protein, not this short fragment. The LKKTET motif sequesters G-actin (monomeric globular actin), influencing its availability for cytoskeletal assembly and thereby modulating cell migration and re-epithelialization.

Role in the blend: 10 mg of the 80 mg vial (~12.5% by mass). Full-length Tβ4 additionally activates integrin-linked kinase and mobilizes epicardial progenitors in cardiac models ^[12] — activities established for the native protein, not demonstrated for the TB-500 fragment. Tβ4 increased re-epithelialization by 42% at 4 days and 61% at 7 days in rat wound models ^[3], induced VEGF expression ^[4], and drove neovascularization in mouse cardiac ischemia ^[12].

Critical regulatory note: thymosin beta-4 is on the WADA Prohibited List under Section S2 (peptide hormones and growth factors), banned at all times in and out of competition. As one of the four components of KLOW, TB-500 implicates anti-doping rules for any athlete or person subject to testing ^[10][11].

The pharmacokinetic mismatch — why one vial cannot serve four arms equally

The four KLOW peptides have markedly different clearance rates. BPC-157 (MW 1419.53 Da) has a very short elimination half-life in rodent models — under approximately 30 minutes in available PK observations. KPV (MW 342.44 Da) and GHK-Cu (MW 402.92 Da) are small tripeptides that clear even faster. The TB-500 fragment behaves differently from the full-length native thymosin beta-4.

A single co-formulated vial therefore cannot hold all four components at matched plasma exposures after administration. The angiogenic arm (BPC-157) may clear before the matrix arm (GHK-Cu) and the anti-inflammatory arm (KPV) have fully distributed. Whether this matters biologically is unknown — it has never been studied. The pharmacokinetic mismatch is a structural caveat in the combination rationale, not a reason to conclude the combination is useless, but also not a reason to assume the four arms are active simultaneously.